Physician profile
Michael Michael Julian Adame
NPI 1730742214
$7,882.87
in general payments reported to CMS, 2019-2025
26 companies · $6,200 in 2025
The $6,200 reported for 2025 was more than what 87% of Allergy & Immunology (Internal Medicine) providers received nationally (typical 2025 total: $681).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $27.15 · 2023: $734 · 2024: $921 · 2025: $6,200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,354 · Consulting Fee: $1,446 · Education: $56.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,353.71 |
| Consulting Fee | $1,446.00 |
| Education | $56.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $2,343.51 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,363.14 | 2023-2025 | Tezspire, Airsupra, Fasenra |
| Regeneron Healthcare Solutions, INC. | $519.53 | 2024-2025 | Dupixent |
| Galderma Laboratories, L.P. | $387.55 | 2025 | Nemluvio |
| Genentech USA, INC. | $366.83 | 2024-2025 | Xolair |
| Ars Pharmaceuticals Operations, INC. | $320.15 | 2025 | Neffy |
| Glaxosmithkline, LLC. | $311.60 | 2023-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Novartis Pharmaceuticals Corporation | $292.54 | 2024-2025 | |
| Csl Behring | $280.99 | 2024-2025 | Hizentra, Haegarda, Andembry |
| Sanofi-Aventis U.S. LLC | $277.59 | 2024-2025 | |
| Pharming Healthcare, INC. | $259.03 | 2023-2025 | Ruconest |
| Amgen INC. | $183.83 | 2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $177.01 | 2024-2025 | Takhzyro, Eohilia, Cuvitru |
| Ionis Pharmaceuticals, INC. | $110.43 | 2025 | Dawnzera |
| Pfizer INC. | $100.00 | 2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $87.42 | 2025 | Yupelri |
| Grifols USA, LLC | $79.12 | 2023-2025 | Xembify, Gamunex-C |
| Biocryst US Sales Co., LLC | $77.63 | 2023-2025 | Orladeyo |
| Lilly USA, LLC | $62.47 | 2025 | Ebglyss, Taltz |
| Organon LLC | $62.42 | 2025 | |
| Blueprint Medicines Corporation | $54.48 | 2025 | Ayvakit |
| Octapharma USA, INC. | $45.00 | 2025 | Panzyga, Cutaquig |
| Verona Pharma, INC. | $42.70 | 2025 | Ohtuvayre |
| Phadia US INC. | $42.03 | 2024 | Immunocap |
| Abbvie INC. | $21.65 | 2025 | |
| Incyte Corporation | $14.22 | 2025 | Opzelura |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Adame listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.